首页> 外文期刊>Blood: The Journal of the American Society of Hematology >A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit

【24h】

A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit

机译：不适合进行诱导化疗的老年急性髓细胞性白血病（AML）患者的Pracinostat和Azacitidine的2期研究：反应和长期生存获益

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共5页
作者
Manero Guillermo Garcia; Atallah Ehab; Khaled Samer K.; Arellano Martha; Patnaik Mrinal M.; Odenike Olatoyosi; Sayar Hamid; Tummala Mohan; Patel Prapti A.; Ghalie Richard G.; Medeiros Bruno C.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit [J] . Manero Guillermo Garcia, Atallah Ehab, Khaled Samer K., Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：不适合进行诱导化疗的老年急性髓细胞性白血病（AML）患者的Pracinostat和Azacitidine的2期研究：反应和长期生存获益
2. Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3(mut+)) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort [J] . Esteve Jordi, Schots Rik, Del Castillo Teresa Bernal, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：多中心，开放标签，3臂研究Gilteritinib，Gilteritinib加氮杂氨酸，或仅在新诊断的FLT3突变（FLT3（MUT +））急性髓性白血病（AML）患者中没有资格对强化诱导化疗的患者：从安全队列中发现
3. Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation-a retrospective national multicenter study [J] . Ram Ron, Gatt Moshe, Merkel Drorit, Annals of hematology . 2017,第4期

机译：二次氮杂氮硝乙汀为老年人或重复患有急性髓性白血病（AML）的患者（AML）没有资格获得同种异体造血细胞移植 - 一个回顾性国家多中心研究
4. Design of optimal disease and patient-specific chemotherapy protocols for the treatment of Acute Myeloid Leukaemia (AML) [C] . E. Pefani, N. Panoskaltsis, A. Mantalaris International Symposium on Process Systems Engineering . 2012

机译：用于治疗急性髓性白血病（AML）的最佳疾病和患者特异性化疗方案的设计
5. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study [D] . Harada Yasuhiko, 原田靖彦 2019

机译：根据2017年日本成人白血病研究组（JALSG）AML201研究治疗的成人急性髓性白血病患者的遗传学预测，根据2017 ELN风险分层进行预后分析
6. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study [O] . Guillermo Garcia-Manero, Yasmin Abaza, Koichi Takahashi, 2019

机译：新诊断为急性髓性白血病的老年患者中的Pracinostat加上azacitidine：2期研究的结果
7. Improved overall survival with Gemtuzumab Ozogamicin (GO) compared with best supportive care (BSC) in elderly patients with untreated acute myeloid leukemia (AML) not considered fit for intensive chemotherapy: final results from the randomized phase III study (AML-19) of the EORTC and gimema leukemia groups [O] . AMADORI, Sergio, SUCIU, Stefan, SELLESLAG, Dominik, 2014

机译：与未经最佳治疗的急性骨髓性白血病（AML）的老年患者相比，吉姆单抗Ozogamicin（GO）与最佳支持治疗（BSC）相比可改善总体生存期：该患者的随机III期研究（AML-19）的最终结果EORTC和生殖器白血病组

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号